caption
stringlengths 6
2.51k
| molecule
stringlengths 1
747
| properties
sequencelengths 1
86
|
|---|---|---|
The molecule is a kinase inhibitor and is glaucoma treatment. | CC(I)c1nnnn1C(C)C | [
"glaucoma treatment",
"kinase inhibitor"
] |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis that impacts barth syndrome and aging. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, tangier disease, and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCC(C)CC | [
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Barth syndrome",
"Aging",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Diabetic heart disease"
] |
The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts diabetic heart disease, barth syndrome, and aging. The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing mitochondrial structure that impacts tangier disease and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Diabetic heart disease",
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Aging",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing mitochondrial structure"
] |
The molecule is a sedative and a ec 3.1.1.7 (acetylcholinesterase) inhibitor that impacts erythema, paralysis, and anxiety. The molecule is a hepatoprotective, a nutrient, and a anti platelet, it impacts cancer preventive and is piscicide. The molecule is a bufocide and a anti aflatoxin, which impacts both hypoglycemia and edema, and is characterized as anti vitiligic. The molecule is a acetylcholinesterase inhibitor and cytochrome-p450 inhibitor, belonging to the anti tumor promoter class of molecules, and it impacts both headache and hypotension. This molecule is a member of the anti inflammatory class and affects collapse, coma, hypertension, and vomiting. The molecule is a anti convulsant and a metabolite that impacts fatigue, nausea, and muscle cramp . The molecule is a anti leukodermic and hepatotoxic agent, belonging to both the anti mutagenic and anti alopecic classes of molecules, and impacts muscle weakness. The molecule is a diabetic-macular-edema inhibitor and a lipolytic, belonging to the calcium channel blocker class of molecules, impacting both depression and tremor, and is molluscicide. | CC(=O)C1=CCC2C3CCC4CC(O)CCC4(C)C3CCC12C | [
"sedative",
"Erythema",
"Paralysis",
"EC 3.1.1.7 (acetylcholinesterase) inhibitor",
"Anxiety",
"piscicide",
"hepatoprotective",
"nutrient",
"cancer preventive",
"anti platelet",
"Hypoglycemia",
"bufocide",
"anti vitiligic",
"Edema",
"anti aflatoxin",
"Headache",
"anti tumor promoter",
"Hypotension",
"acetylcholinesterase inhibitor",
"cytochrome-P450 inhibitor",
"Collapse",
"Coma",
"Hypertension",
"Vomiting",
"anti inflammatory",
"Fatigue",
"anti convulsant",
"metabolite",
"Nausea",
"Muscle cramp ",
"anti leukodermic",
"anti mutagenic",
"anti alopecic",
"Muscle weakness",
"hepatotoxic agent",
"Depression",
"calcium channel blocker",
"Tremor",
"diabetic-macular-edema inhibitor",
"molluscicide",
"lipolytic"
] |
It impacts cardiovascular disease, seizure, diabetes mellitus, and colorectal cancer. It has an effect on breast cancer, and impacts parkinson's disease, stomach cancer, and alzheimer's disease. | CC/C=C\CCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O)OC(=O)CCC/C=C/C=C\C(O)C/C=C\C/C=C\CCCCC | [
"Cardiovascular disease",
"Seizure",
"Diabetes mellitus",
"Colorectal cancer",
"Breast cancer",
"Parkinson's disease",
"Stomach cancer",
"Alzheimer's Disease"
] |
The molecule is a tyrosine kinase inhibitor. | Cc1ccoc1C(=O)Nc1cccc(C#CC2C=NC=C(C(=O)Nc3cccc(CC(=O)N4CCC(O)C4)c3O)C2=S)c1 | [
"tyrosine kinase inhibitor"
] |
The molecule is a depression treatment that impacts metabolic syndrome treatment. | Cc1cc(C(=O)c2ccccc2F)ccc1C(=O)O | [
"depression treatment",
"metabolic syndrome treatment"
] |
The molecule is both a waste product and a nutrient. | O=C(O)[C@H]1O[C@@H](Oc2cc([C@H]3Oc4cc(O)cc(O)c4C[C@H]3O)ccc2O)[C@H](O)[C@@H](O)[C@@H]1O | [
"Waste product",
"nutrient"
] |
The molecule is a lipoxygenase inhibitor, anti inflammatory, anti allergic and belongs to the leukotriene antagonist class of molecules. | CC(=O)O.Clc1ccc2ccc(COc3ccc(Nc4c(Cl)cccc4Cl)cc3)nc2c1 | [
"lipoxygenase inhibitor",
"leukotriene antagonist",
"anti inflammatory",
"anti allergic"
] |
The molecule is a anti inflammatory, a lipoxygenase inhibitor, and a 5lipoxygenase inhibitor, belonging to both the cardiovascular treatment and autoimmune treatment classes, and is anti inflammatory agent. | COc1ccc(OCc2cccc(C(=O)O)c2)cc1 | [
"cardiovascular treatment",
"anti inflammatory",
"lipoxygenase inhibitor",
"autoimmune treatment",
"anti inflammatory agent",
"5lipoxygenase inhibitor"
] |
The molecule is a anti oselective. | CCOC(=O)C1(C#N)C=C1c1cccc(N)c1 | [
"anti oselective"
] |
The molecule is a energy storage, membrane stabilizer, energy source, inflammatory that has an effect on lipotoxicity and impacts metabolic syndrome. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCC(C)C | [
"Energy storage",
"Lipotoxicity",
"Membrane stabilizer",
"Metabolic syndrome",
"Energy source",
"inflammatory"
] |
The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts diabetic heart disease, aging, and tangier disease. The molecule is a stabilizing mitochondrial structure, apoptosis, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and barth syndrome. | CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Cholesterol translocation",
"Aging",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] |
The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts aging, diabetic heart disease, and tangier disease. The molecule is a apoptosis, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Aging",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] |
The molecule is a anti parasitic. | O=C(NCC=NO)c1ccc(C2=NOC(c3cc(Cl)cc(Cl)c3)(C(F)(F)F)C2)c2ccccc12 | [
"anti parasitic"
] |
The molecule is a fat storage, nutrient, membrane stabilizer, inflammatory, energy storage that impacts atherosclerosis. The molecule is a energy source that impacts both pancreatitis and obesity. It has an effect on cancer, and impacts cardiovascular disease, metabolic syndrome, and thyroxine treatment. | CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCC(C)CC | [
"Fat storage",
"nutrient",
"Atherosclerosis",
"Membrane stabilizer",
"inflammatory",
"Energy storage",
"Pancreatitis",
"Energy source",
"Obesity",
"Cardiovascular disease",
"Cancer",
"Metabolic syndrome",
"Thyroxine treatment"
] |
The molecule is a mglur5 modulator. | CC1NCCn2c(-c3cccs3)nnc21 | [
"mglur5 modulator"
] |
The molecule is anti bacterial and anti fungal. | Cn1cncc1-c1ccc(OCC2COC(Cn3cncn3)(c3ccc(Cl)cc3Cl)O2)cc1.O=[N+]([O-])O | [
"anti bacterial",
"anti fungal"
] |
The molecule is a anti obesity and belongs to the npy y5 antagonist class of molecules. | CC(C)(C)S(=O)(=O)NC1=CC=C(C(=O)Nc2cccc(C(O)NC3CCCCC3)c2)CC1 | [
"anti obesity",
"npy y5 antagonist"
] |
The molecule is a fat storage that impacts both cardiovascular disease and atherosclerosis. The molecule is a nutrient and a thyroxine treatment, impacting both pancreatitis and metabolic syndrome. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\CCCCCCCC | [
"Cardiovascular disease",
"Fat storage",
"Atherosclerosis",
"Pancreatitis",
"nutrient",
"Thyroxine treatment",
"Metabolic syndrome"
] |
The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase, cholesterol translocation that impacts non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure that impacts barth syndrome, aging, tangier disease, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Aging",
"Tangier disease",
"Diabetic heart disease"
] |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis that impacts aging and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts tangier disease, non-alcoholic fatty liver disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Aging",
"Apoptosis",
"Diabetic heart disease",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Barth syndrome"
] |
It impacts breast cancer, alzheimer's disease, seizure, and cardiovascular disease. It impacts colorectal cancer, stomach cancer, diabetes mellitus, and parkinson's disease. | CCCCCCCCCCCCCCCCCC(=O)O[C@@H]1COC(=O)CCC/C=C\C[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](OP(=O)(O)OC1)[C@H](OP(=O)(O)O)[C@H](O)[C@@H](/C=C/[C@@H](O)CCCCC)C(=O)C[C@@H]2O | [
"Breast cancer",
"Alzheimer's Disease",
"Seizure",
"Cardiovascular disease",
"Colorectal cancer",
"Stomach cancer",
"Diabetes mellitus",
"Parkinson's disease"
] |
The molecule is a cholesterol translocation and a energy storage, impacting both tangier disease and diabetic heart disease. The molecule is a food additive, a emulsifier, and a nutritional supplement, it impacts barth syndrome and is smooth. The molecule is a apoptosis, a surfactant, and a stabilizing mitochondrial structure, and it impacts non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase, energy source, proton trap for oxidative phosphorylation, membrane stabilizer that impacts aging. | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Tangier disease",
"Diabetic heart disease",
"Cholesterol translocation",
"Energy storage",
"food additive",
"Smooth",
"Emulsifier",
"Barth syndrome",
"Nutritional supplement",
"Apoptosis",
"surfactant",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Energy source",
"Proton trap for oxidative phosphorylation",
"Membrane stabilizer"
] |
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts diabetic heart disease, tangier disease, and barth syndrome. The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation that impacts non-alcoholic fatty liver disease and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Diabetic heart disease",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Aging",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation"
] |
The molecule is a nutrient that affects cervical cancer by impacting breast cancer, atherosclerosis, and ulcerative colitis. | CC/C=C\C/C=C\CC(O)/C=C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCc1oc(CCCCC)c(C)c1C)COP(=O)([O-])OCC[N+](C)(C)C | [
"Cervical cancer",
"Breast cancer",
"Atherosclerosis",
"Ulcerative colitis",
"nutrient"
] |
It belongs to both the adenosine antagonist and anti depressant classes of molecules. | CCn1c(=O)c2[nH]c(C=Cc3cccc(Cl)c3)nc2n(CC)c1=O | [
"adenosine antagonist",
"anti depressant"
] |
The molecule is a stabilizing cytochrome oxidase, apoptosis, proton trap for oxidative phosphorylation that impacts aging and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts barth syndrome, non-alcoholic fatty liver disease, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Aging",
"Diabetic heart disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Tangier disease"
] |
The molecule is a inflammatory that impacts atherosclerosis, metabolic syndrome, pancreatitis, cardiovascular disease, and cancer. The molecule is a fat storage, a nutrient, and a energy source. The molecule is a membrane stabilizer and energy storage, belonging to the thyroxine treatment class of molecules, and impacts obesity. | CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)COC(=O)CCCCCCCCCCC(C)CC | [
"inflammatory",
"Atherosclerosis",
"Metabolic syndrome",
"Pancreatitis",
"Cardiovascular disease",
"Cancer",
"Fat storage",
"nutrient",
"Energy source",
"Membrane stabilizer",
"Obesity",
"Thyroxine treatment",
"Energy storage"
] |
The molecule is a member of the thyroxine treatment class and affects both metabolic syndrome and pancreatitis. The molecule is a fat storage and a nutrient, impacting both cardiovascular disease and atherosclerosis. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Metabolic syndrome",
"Pancreatitis",
"Thyroxine treatment",
"Fat storage",
"nutrient",
"Cardiovascular disease",
"Atherosclerosis"
] |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, tangier disease, and aging. The molecule is a stabilizing mitochondrial structure, apoptosis, cholesterol translocation that impacts barth syndrome and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease"
] |
The molecule is a energy source, inflammatory, energy storage, membrane stabilizer that impacts lipotoxicity and metabolic syndrome. | CCCCCCCCCCCCC(=O)OC[C@@H](O)COC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Energy source",
"Lipotoxicity",
"Metabolic syndrome",
"inflammatory",
"Energy storage",
"Membrane stabilizer"
] |
It has an effect on low driving voltage. | Brc1cc2c3ccccc3c3ccccc3c2cc1-c1nc(-c2ccccc2)nc(-c2ccc3c(c2)oc2ccccc23)n1 | [
"low driving voltage"
] |
The molecule is a energy storage and a fat storage, which impacts cardiovascular disease, cancer, and metabolic syndrome, and is characterized as thyroxine treatment. The molecule is a membrane stabilizer and inflammatory, and it impacts pancreatitis. The molecule is a energy source and a nutrient, impacting both obesity and atherosclerosis. | CCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Cardiovascular disease",
"Thyroxine treatment",
"Energy storage",
"Fat storage",
"Cancer",
"Metabolic syndrome",
"Membrane stabilizer",
"inflammatory",
"Pancreatitis",
"Energy source",
"nutrient",
"Obesity",
"Atherosclerosis"
] |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts aging, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a cholesterol translocation, apoptosis, stabilizing cytochrome oxidase that impacts barth syndrome and tangier disease. | CCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Aging",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Apoptosis",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Tangier disease"
] |
The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, aging, and barth syndrome. The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease and non-alcoholic fatty liver disease. | CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCC(C)CC | [
"Apoptosis",
"Diabetic heart disease",
"Aging",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation"
] |
It influences both stomach cancer and colorectal cancer, as well as affecting seizure and cardiovascular disease. It has an effect on breast cancer, and impacts diabetes mellitus, alzheimer's disease, and parkinson's disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCC[C@@H](C)O)COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O | [
"Seizure",
"Cardiovascular disease",
"Stomach cancer",
"Colorectal cancer",
"Diabetes mellitus",
"Breast cancer",
"Alzheimer's Disease",
"Parkinson's disease"
] |
The molecule is a protein kinase inhibitor and is cancer treatment. | COc1cc2c(Oc3cccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)c3Cl)ccnc2cc1OCCCC(=O)[O-].[Na+] | [
"protein kinase inhibitor",
"cancer treatment"
] |
The molecule is both a serotonin reuptake inhibitor and a norepinephrine reuptake inhibitor. | COCC12CNCCC1(c1ccc3ccccc3c1)C2.Cl | [
"serotonin reuptake inhibitor",
"norepinephrine reuptake inhibitor"
] |
The molecule is a membrane stabilizer, energy storage, fat storage, inflammatory that impacts obesity and cancer. The molecule is a nutrient that impacts both cardiovascular disease and pancreatitis. The molecule is a energy source and belongs to the thyroxine treatment class of molecules, impacting both metabolic syndrome and atherosclerosis. | CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCC(C)C | [
"Membrane stabilizer",
"Energy storage",
"Fat storage",
"inflammatory",
"Obesity",
"Cancer",
"Cardiovascular disease",
"Pancreatitis",
"nutrient",
"Metabolic syndrome",
"Atherosclerosis",
"Thyroxine treatment",
"Energy source"
] |
The molecule is a sodium channel inhibitor that impacts pain treatment. | O=C(O)C1C=C(C(F)(F)F)CN1C(=O)c1cc(C2CC2)c(OCC23CC4CC5CC(C2)C5(C4)C3)cc1F | [
"pain treatment",
"sodium channel inhibitor"
] |
The molecule is a cholesterol translocation and a apoptosis that impacts non-alcoholic fatty liver disease, tangier disease, and diabetic heart disease. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts barth syndrome and aging. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Diabetic heart disease",
"Cholesterol translocation",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Aging"
] |
It belongs to the organic light-emitting device class of molecules. | c1ccc(-c2cc(-c3ccc4ccccc4c3)cc(N(c3ccc4oc5c6ccccc6ccc5c4c3)c3ccc4c5ccccc5n(-c5ccc6ccccc6c5)c4c3)c2)cc1 | [
"organic light-emitting device"
] |
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts tangier disease, barth syndrome, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and aging. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Tangier disease",
"Barth syndrome",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Apoptosis",
"Stabilizing mitochondrial structure"
] |
The molecule is a bromodomain inhibitor and is cancer treatment. | C=CC(=O)N(C)c1cc(O)cc(C(OC(=O)C(C)(C)C)c2ccccc2)c1 | [
"cancer treatment",
"bromodomain inhibitor"
] |
The molecule is a kinase inhibitor and belongs to the cancer treatment class of molecules. | CN1CCN(Cc2cccc(-c3cc(-c4ccc5cn(Cc6ccccc6)nc5c4)c4c(N)ncnn34)c2)CC1 | [
"cancer treatment",
"kinase inhibitor"
] |
The molecule is a dgat inhibitor and belongs to both the obesity treatment and anti obesity classes of molecules. | Cc1ccc(F)c(NC(=O)Nc2ccc3c(c2)CCN(C(=O)OC2CCC(CC(=O)O)CC2)C3)c1 | [
"obesity treatment",
"dgat inhibitor",
"anti obesity"
] |
It belongs to the crf antagonist class of molecules. | CCCCC(O)c1nc(C)nc2c1c(C)c(C)n2-c1c(C)cc(C)cc1C | [
"crf antagonist"
] |
The molecule is a phosphodiesterase inhibitor. | CCc1nn(CCCOC(=O)c2cccc(C)n2)c2c1C(=O)NCCCOCCC2 | [
"phosphodiesterase inhibitor"
] |
The molecule is a food additive, proton trap for oxidative phosphorylation, cholesterol translocation, energy storage. The molecule is a energy source and a stabilizing mitochondrial structure that impacts aging, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a membrane stabilizer and a emulsifier, it impacts barth syndrome, and is smooth. The molecule is a apoptosis, surfactant, nutritional supplement, stabilizing cytochrome oxidase that impacts tangier disease. | CCC(C)CCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"food additive",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Energy storage",
"Aging",
"Energy source",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Membrane stabilizer",
"Emulsifier",
"Barth syndrome",
"Smooth",
"Apoptosis",
"surfactant",
"Tangier disease",
"Nutritional supplement",
"Stabilizing cytochrome oxidase"
] |
It belongs to the anti cancer class of molecules. | C=CC=CC=C1CSC(=NNC(=O)C=Cc2cccnc2)N1C | [
"anti cancer"
] |
The molecule is a apoptosis that impacts barth syndrome, tangier disease, aging, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, cholesterol translocation that impacts diabetic heart disease. | CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Barth syndrome",
"Tangier disease",
"Apoptosis",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation"
] |
The molecule is a calcium receptor antagonist. | CCc1cc(CC2CCCN2CC(O)COC(CC)c2ccc(C)cc2CCC(=O)O)ccc1Cl | [
"calcium receptor antagonist"
] |
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts barth syndrome, aging, and tangier disease. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCCCC | [
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Aging",
"Apoptosis",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Stabilizing mitochondrial structure"
] |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts diabetic heart disease and barth syndrome. The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, aging, and tangier disease. | CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Barth syndrome",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Aging",
"Tangier disease",
"Stabilizing cytochrome oxidase"
] |
The molecule is a cyclindependent kinase inhibitor and belongs to the cancer treatment class of molecules, with the characteristic of being kinase modulator. | CC1CCC(Nc2ncc3c(n2)N(C2CCCC2)C(=O)C2(CCNC2=O)C3)CC1 | [
"cyclindependent kinase inhibitor",
"cancer treatment",
"kinase modulator"
] |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis, stabilizing mitochondrial structure that impacts tangier disease. The molecule is a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, diabetic heart disease, barth syndrome, and aging. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCC(C)C | [
"Tangier disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Aging"
] |
The molecule is a nutrient, membrane stabilizer, energy source, fat storage that impacts cardiovascular disease and pancreatitis. The molecule is a inflammatory and energy storage, and it impacts atherosclerosis. The molecule is thyroxine treatment and impacts metabolic syndrome, obesity, and cancer. | CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"nutrient",
"Cardiovascular disease",
"Membrane stabilizer",
"Energy source",
"Fat storage",
"Pancreatitis",
"Atherosclerosis",
"inflammatory",
"Energy storage",
"Thyroxine treatment",
"Metabolic syndrome",
"Obesity",
"Cancer"
] |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease and tangier disease. The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts barth syndrome, aging, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Apoptosis",
"Aging",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation"
] |
The molecule is a anti cancer, a anti cancer agent, and estrogen receptor modulator. | Oc1ccc2c(c1)CCCC(c1cnc3[nH]ccc3c1)=C2c1ccc(OC2CCC(CCCCCF)CC2)cc1 | [
"anti cancer",
"estrogen receptor modulator",
"anti cancer agent"
] |
The molecule is a energy storage, a surfactant, and a emulsifier. The molecule is a nutrient, a membrane stabilizer, a energy source, and hemolytic. | COC1=CC(=O)c2ccc(OC)cc21 | [
"Energy storage",
"surfactant",
"Emulsifier",
"nutrient",
"Membrane stabilizer",
"Energy source",
"hemolytic"
] |
The molecule is a anti inflammatory, anti cancer, and anti bodydrug conjugate compound. | CCC(C)NC(=O)c1cc2cc(c1)CSPSC2 | [
"anti inflammatory",
"anti bodydrug conjugate",
"anti cancer"
] |
The molecule is a flavoring agent which is benzophenone, green, and plastic; further, it is clean and balsamic. | CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(O)C(=O)C(CC2=C(O)C(=O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)=C(O)C2=O)=C(O)C1=O | [
"benzophenone",
"Flavoring agent",
"green",
"plastic",
"clean",
"balsamic"
] |
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts aging, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts tangier disease and barth syndrome. | CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Aging",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome"
] |
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, tangier disease, and diabetic heart disease. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis that impacts aging and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Aging",
"Barth syndrome",
"Apoptosis"
] |
It belongs to the anti coagulant class of molecules. | O=c1ocnc2c1N=CCN2c1ccccc1F | [
"anti coagulant"
] |
The molecule is a nutrient, ethereal, gravy, and chemical. The molecule is a food and nutrition, bacon, meaty, roast, beef. | Cc1oc2ccccc2c1C | [
"ethereal",
"nutrient",
"gravy",
"chemical",
"bacon",
"Food and nutrition",
"meaty",
"roast",
"beef"
] |
The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts aging, non-alcoholic fatty liver disease, and tangier disease. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts diabetic heart disease and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Barth syndrome",
"Cholesterol translocation"
] |
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts non-alcoholic fatty liver disease, aging, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing mitochondrial structure that impacts barth syndrome and tangier disease. | CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Aging",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Apoptosis",
"Tangier disease",
"Stabilizing mitochondrial structure"
] |
The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts tangier disease, aging, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease and barth syndrome. | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Tangier disease",
"Aging",
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Barth syndrome"
] |
The molecule is a ec 3.1.1.7 (acetylcholinesterase) inhibitor which is terpene, peppery, and camphoraceous; further, it is pine and herbal. | Nc1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H]2O)c(=O)n1 | [
"terpene",
"EC 3.1.1.7 (acetylcholinesterase) inhibitor",
"peppery",
"camphoraceous",
"pine",
"herbal"
] |
The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts barth syndrome and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts tangier disease, diabetic heart disease, and aging. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCC | [
"Apoptosis",
"Barth syndrome",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Aging"
] |
The molecule is a energy storage and a proton trap for oxidative phosphorylation, impacting both aging and non-alcoholic fatty liver disease. The molecule is a surfactant, apoptosis, energy source that impacts tangier disease and barth syndrome. The molecule is a stabilizing cytochrome oxidase, a emulsifier, a nutritional supplement, and smooth. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, membrane stabilizer, food additive that impacts diabetic heart disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Energy storage",
"Aging",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"surfactant",
"Tangier disease",
"Apoptosis",
"Energy source",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Smooth",
"Emulsifier",
"Nutritional supplement",
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Membrane stabilizer",
"food additive"
] |
The molecule is anti coagulant. | C=C(C)c1ccc(CC(NC(=O)c2cc3ccc(OC4(C(C)(C)C)CCCCC4)cc3c(CC3CCCC3)n2)C(=O)OC)s1 | [
"anti coagulant"
] |
The molecule is a stabilizing mitochondrial structure that impacts aging, diabetic heart disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a apoptosis, cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts tangier disease. | CCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Aging",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation"
] |
The molecule is anti inflammatory. | COC(=O)c1ccccc1Nc1ccnc2c(SC(F)(F)F)cccc12 | [
"anti inflammatory"
] |
The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, cholesterol translocation that impacts tangier disease and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts barth syndrome, non-alcoholic fatty liver disease, and aging. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCC(C)CC | [
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Diabetic heart disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Aging"
] |
The molecule is a optoelectronic. | Cc1cc(-c2ccc3c4ccc(-c5cc(C(F)(F)F)cc(C(F)(F)F)c5)cc4n(-c4cc(C#N)cc(-n5c6cc(-c7cc(C(F)(F)F)cc(C(F)(F)F)c7)ccc6c6ccc(-c7cc(C(F)(F)F)cc(C(F)(F)F)c7)cc65)c4-c4ccncc4)c3c2)cc(C(F)(F)F)c1 | [
"optoelectronic"
] |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts diabetic heart disease and aging. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts non-alcoholic fatty liver disease, barth syndrome, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Tangier disease",
"Apoptosis"
] |
The molecule is hyperlipidemia treatment and it impacts obesity treatment. | COc1cc(OCc2cccnc2)ccc1-c1cnc(-c2ccc(F)cc2)[nH]1 | [
"hyperlipidemia treatment",
"obesity treatment"
] |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts barth syndrome, aging, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Barth syndrome",
"Apoptosis",
"Aging",
"Stabilizing mitochondrial structure",
"Diabetic heart disease"
] |
It belongs to the anti bacterial class of molecules. | Br.CCCCCCCCC=CCCCCCCCCOCN1C=CC(CC)=C(C(=O)O)C1 | [
"anti bacterial"
] |
The molecule is a nutrient. | O=C(O)C(O)C(=O)O | [
"nutrient"
] |
The molecule is a hdac6 inhibitor. | NNC(=O)c1ccc(CN(c2ccc(F)cc2)S(=O)(=O)N2CCOCC2)cc1 | [
"hdac6 inhibitor"
] |
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis that impacts non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase that impacts tangier disease, diabetic heart disease, aging, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCC | [
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Tangier disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Barth syndrome"
] |
The molecule is a membrane stabilizer, a energy storage, and a surfactant, and it impacts aging. The molecule is a energy source, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts tangier disease and barth syndrome. The molecule is a emulsifier and a stabilizing cytochrome oxidase, it impacts non-alcoholic fatty liver disease, and is smooth. The molecule is a cholesterol translocation, nutritional supplement, apoptosis, food additive that impacts diabetic heart disease. | CCC(C)CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"Membrane stabilizer",
"Energy storage",
"Aging",
"surfactant",
"Energy source",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Barth syndrome",
"Emulsifier",
"Smooth",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Diabetic heart disease",
"Nutritional supplement",
"Apoptosis",
"food additive"
] |
The molecule is a nutrient that impacts diabetes mellitus type 2, alzheimer's disease, parkinson's disease, and non-alcoholic fatty liver disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCC/C=C\C/C=C\C/C=C\C=C\[C@@H](O)CCCCC | [
"Diabetes mellitus type 2",
"Alzheimer's Disease",
"Parkinson's disease",
"nutrient",
"Non-alcoholic fatty liver disease"
] |
The molecule is a electronic device and fluorescent, belonging to both the electroluminescent and organic electroluminescent compound classes of molecules, and has an effect on organic electroluminescence. | CC(C)c1cccc2c1oc1c(N(c3ccccc3)c3ccc4cc5c6cc(-c7ccccc7)cc7c8cc9ccc(N(c%10ccccc%10)c%10cccc%11c%10oc%10c(C(C)C)cccc%10%11)cc9cc8n(c5cc4c3)c67)cccc12 | [
"electroluminescent",
"electronic device",
"organic electroluminescence",
"fluorescent",
"organic electroluminescent compound"
] |
The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts diabetic heart disease and tangier disease. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Stabilizing mitochondrial structure",
"Aging",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease"
] |
The molecule is a stabilizing cytochrome oxidase that impacts barth syndrome, aging, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis that impacts tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Barth syndrome",
"Aging",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Apoptosis"
] |
The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts aging, non-alcoholic fatty liver disease, and tangier disease. The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, apoptosis that impacts diabetic heart disease and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC | [
"Aging",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Apoptosis"
] |
The molecule is a metalloprotease inhibitor. | Cc1c(C(=O)O)ccc2c1CCC2NC(=O)c1cc(C(=O)NCc2cc(F)c(F)c(F)c2)nc2c(C(=O)Nc3ccccc3Cl)cnn12 | [
"metalloprotease inhibitor"
] |
The molecule is a energy storage, a nutrient, and a membrane stabilizer. The molecule is a emulsifier, surfactant, energy source, drug. | CC1(C)O[C@H]2OC(=O)C=C[C@]23C1CC(=O)[C@]1(C)C3CC[C@@]2(C)[C@H](c3ccoc3)OC(=O)[C@H]3O[C@]321 | [
"Energy storage",
"nutrient",
"Membrane stabilizer",
"Emulsifier",
"surfactant",
"Energy source",
"Drug"
] |
The molecule is a fat storage and thyroxine treatment, and it impacts cardiovascular disease. The molecule is a nutrient that impacts atherosclerosis, metabolic syndrome, and pancreatitis. | CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCC/C=C\CCCCCC)OC(=O)CCCCCC/C=C\C/C=C\C/C=C\CCCCC | [
"Cardiovascular disease",
"Thyroxine treatment",
"Fat storage",
"Atherosclerosis",
"Metabolic syndrome",
"nutrient",
"Pancreatitis"
] |
The molecule is a membrane stabilizer and fat storage, affecting cancer, and impacting pancreatitis, cardiovascular disease, and atherosclerosis. The molecule is a inflammatory that impacts both obesity and metabolic syndrome. The molecule is a energy storage, a nutrient, and a energy source, and it impacts thyroxine treatment. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)C | [
"Cancer",
"Membrane stabilizer",
"Pancreatitis",
"Cardiovascular disease",
"Atherosclerosis",
"Fat storage",
"inflammatory",
"Obesity",
"Metabolic syndrome",
"Energy storage",
"Thyroxine treatment",
"nutrient",
"Energy source"
] |
The molecule is a inflammatory, fat storage, nutrient that impacts obesity, cancer, and pancreatitis. The molecule is a energy storage that impacts both cardiovascular disease and atherosclerosis. The molecule is a energy source and membrane stabilizer, belonging to the thyroxine treatment class of molecules, and impacts metabolic syndrome. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"inflammatory",
"Obesity",
"Fat storage",
"nutrient",
"Cancer",
"Pancreatitis",
"Cardiovascular disease",
"Atherosclerosis",
"Energy storage",
"Thyroxine treatment",
"Energy source",
"Membrane stabilizer",
"Metabolic syndrome"
] |
The molecule is a mmp13 inhibitor, a matrix metalloproteinase inhibitor, and a cox2 inhibitor. | CCC=CCn1c(=O)c2cc(C(=O)NCc3cccc(OC)c3)sc2n(C)c1=O | [
"mmp13 inhibitor",
"matrix metalloproteinase inhibitor",
"cox2 inhibitor"
] |
The molecule is atherosclerosis treatment. | COCC(=O)OCOC(=O)N1CCC(c2cccc(CC(C)(C)C)c2)CC1 | [
"atherosclerosis treatment"
] |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts barth syndrome, diabetic heart disease, and aging. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C | [
"Barth syndrome",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Aging",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation"
] |
The molecule is a stabilizing cytochrome oxidase that impacts aging, barth syndrome, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts tangier disease. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCCCCC | [
"Aging",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Cholesterol translocation",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Apoptosis"
] |